Navigation Links
Pharmaxis Closes Share Purchase Plan
Date:6/29/2009

SYDNEY, June 29 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced it had raised A$7.2 million from its Share Purchase Plan which closed on 24 June 2009. Shareholders of the company were given the opportunity to purchase up to $5,000 worth of shares each at the $2.35 price paid by institutional investors in the recent placement.

A total of 1,584 shareholders participated in the plan under which the company will issue approximately 3 million new shares and receive funds of approximately $7.2 million.

Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, "We are very encouraged and appreciative of the level of support from our shareholders. The total proceeds of the placement and share purchase plan of $54 million puts us in a strong position from which to take our products to the global markets."

Shares will be issued today, 30 June 2009, and are expected to be listed on the Australian Securities Exchange on 2 July 2009. Holding statements will be posted on or about 1 July 2009.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson
     Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

     United States:
     Brandon Lewis
     Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
2. New Pharmaxis Board Appointment
3. Pharmaxis Investor Conference Call
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Pharmaxis Builds Senior Management Team
6. Pharmaxis Investor Conference Call
7. Pharmaxis Aridol Approved for Sale in Switzerland
8. Pharmaxis Investor Conference Call
9. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
10. New Pharmaxis Board Appointment
11. Pharmaxis Aridol Authorised for Sale in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... WASHINGTON , Feb. 11, 2016   BioInformant ... strategic report, "Stem Cell Research Products, Opportunities, Tools, and ... 2020. ... specialize in the stem cell industry, BioInformant has more ... of the stem cell market, by stem cell type. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... its new stem cell treatment clinic in Quito, Ecuador. The new facility will ... trauma applications to patients from around the world. , The new GSCG ...
(Date:2/10/2016)... 10, 2016  The Maryland House of Delegates and ... that University of Maryland School of Medicine Dean ... of Maryland Medical System President and CEO Robert ... the highest honor given to the public by the ... Dean Reece and Mr. Chrencik for their contributions ...
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
Breaking Biology Technology:
(Date:2/11/2016)... , Feb. 11, 2016  Vigilant Solutions announces today that ... are being used by Lee,s Summit ... recent location and arrest of a homicide suspect. ... covers around 65 square miles and is home to ... Department has a single mobile license plate reader system and ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ) ... "Global Facial Recognition Market 2016-2020" report ... ) has announced the addition of the ... report to their offering. --> ... announced the addition of the "Global ...
(Date:2/3/2016)... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ... "Emotion Detection and Recognition Market by Technology ... Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020" report to ... ) has announced the addition of the ...
Breaking Biology News(10 mins):